Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis

NCT01874340 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
28
Enrollment
INDUSTRY
Sponsor class

Stopped Study terminated early based upon development of another anti-IL17 fully human monoclonal antibody with better potential for treating MS patients

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals